Novel Insights Into the Pathogenesis of Diabetic Cardiomyopathy and Pharmacological Strategies

Novel Insights Into the Pathogenesis of Diabetic Cardiomyopathy and Pharmacological Strategies

Diabetic cardiomyopathy (DCM) is a severe complication of diabetes developed mainly in poorly controlled patients. In DCM, several clinical manifestations as well as cellular and molecular mechanisms contribute to its phenotype. The production of reactive oxygen species (ROS), chronic low-grade infl...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in cardiovascular medicine Vol. 8; p. 707336
Main Authors: Muñoz-Córdova, Felipe, Hernández-Fuentes, Carolina, Lopez-Crisosto, Camila, Troncoso, Mayarling F, Calle, Ximena, Guerrero-Moncayo, Alejandra, Gabrielli, Luigi, Chiong, Mario, Castro, Pablo F, Lavandero, Sergio
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 23-12-2021
Subjects:
cardiomyopathy
Cardiovascular Medicine
diabetes
heart
inflammation
mitochondria
pyroptosis
pyroptosis
mitophagy
inflammation
mitochondria
cardiomyopathy
diabetes
heart
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetic cardiomyopathy (DCM) is a severe complication of diabetes developed mainly in poorly controlled patients. In DCM, several clinical manifestations as well as cellular and molecular mechanisms contribute to its phenotype. The production of reactive oxygen species (ROS), chronic low-grade inflammation, mitochondrial dysfunction, autophagic flux inhibition, altered metabolism, dysfunctional insulin signaling, cardiomyocyte hypertrophy, cardiac fibrosis, and increased myocardial cell death are described as the cardinal features involved in the genesis and development of DCM. However, many of these features can be associated with broader cellular processes such as inflammatory signaling, mitochondrial alterations, and autophagic flux inhibition. In this review, these mechanisms are critically discussed, highlighting the latest evidence and their contribution to the pathogenesis of DCM and their potential as pharmacological targets.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Cardiovascular Biologics and Regenerative Medicine, a section of the journal Frontiers in Cardiovascular Medicine
These authors have contributed equally to this work
Reviewed by: Anna Planavila, University of Barcelona, Spain; Shyam Sundar Nandi, University of Nebraska Medical Center, United States; Zhengyuan Xia, The University of Hong Kong, Hong Kong SAR, China
Edited by: VijayaKumar Sukumaran, Qatar University, Qatar
ISSN:2297-055X
2297-055X
DOI:10.3389/fcvm.2021.707336